Back

Notification report


Full notification file


General information

Notification Number
B/BE/15/BVW1

Member State to which the notification was sent
Belgium

Date of acknowledgement from the Member State Competent Authority
17/07/2015

Title of the Project
A Phase 1b/3, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of
Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma (20110265)


Proposed period of release:
01/04/2016 to 31/01/2023

Name of the Institute(s) or Company(ies)
Amgen Limited, UK, On behalf of Amgen Inc. (study sponsor);


3. Is the same GMO release planned elsewhere in the Community?
Yes:
Belgium; Germany; Spain; France; Greece; Netherlands; Sweden;

Has the same GMO been notified elsewhere by the same notifier?
Yes

If yes, notification number(s):


GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Genus: Simplexvirus
Species: Talimogene laherparepvec is a recombinant of a wild type Herpes simplex
virus 1 (HSV-1) strain JS1, with genes ICP34.5 and ICP47 deleted and hGM-CSF inserted


Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
HSV-1SimplexvirusHerpes simplex virus 1-JS1 (ECACC Accession Number 01010209)-

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known